Search Results
Oct 21, 2025, 11:50 ET Pioneering Physician-Scientist Dr. Francis S. Collins Joins ImmunoBrain Board of Directors
Collins coordinated an international consortium of laboratories as part of the Human Genome Project to produce the first complete sequence of the human DNA instruction book in 2003. He has been recognized for his many contributions to science, medicine, and society with the Presidential Medal of Freedom,
More news about: ImmunoBrain Checkpoint Inc.
Oct 21, 2025, 10:30 ET Shay Capital Letter to the Board of Bark, Inc.
moat, strategic plans must be drawn up at the Board level to aggressively expand the company's product categories to include vitamins & supplements, DNA testing kits for dogs and other wellness products while ramping up product experimentation across the portfolio. With proprietary data on over 6 million
More news about: Shay Capital LLC
Oct 21, 2025, 08:05 ET Clinical Proof-of-Concept Data for DNA-Encoded Monoclonal Antibodies (DMAbs) Published in Nature Medicine
About INOVIO's DNA Medicines Platform INOVIO's DNA medicines platform has two innovative components: precisely designed DNA plasmids, delivered by INOVIO's proprietary investigational medical device, CELLECTRA®. INOVIO uses proprietary technology to design its DNA plasmids, which are
More news about: INOVIO Pharmaceuticals, Inc.
Oct 21, 2025, 08:05 ET The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners
he served as Chief Medical Officer at Corvus Pharmaceuticals (Nasdaq: CRVS), and held positions of increasing responsibility at Genentech (Nasdaq: DNA), where he notably served as group medical director and global development lead for venetoclax. Dr. Mobasher earned his M.D. from Tehran University,
More news about: Institute for Follicular Lymphoma Innovation (IFLI)
Oct 21, 2025, 00:48 ET EXEED Co-Creation Workshop: Texxeract Technology Premieres, Three New Models Debut with the New Family Design Language
its sporty character with a revised bumper, air-guiding side skirts, and a large rear diffuser. All three models inherit the Stellar Concept design DNA, showcasing the distinctive charm of EXEED's new family design language. Conclusion:
More news about: EXEED
Oct 20, 2025, 14:30 ET Breakthrough Discovery Identifies the Cause of Bipolar Disorder
for accelerated DNA damage. According to Dr. Walsh, these impairments usually are not sufficient to produce the illness during childhood or adolescence. However, several years of relentless free-radical assault and DNA damage eventually
More news about: Walsh Research Institute
Oct 20, 2025, 09:03 ET Accessible Pricing and Smart Leasing: VinFast's Key Strategy for Global Expansion
markets was a bold move. But as VinFast often emphasizes, a spirit of daring - the courage to think boldly and act decisively - is embedded in the brand's DNA. Throughout its rapid expansion, VinFast has maintained a commitment to customer feedback, continuously refining both its products
More news about: VinFast
Oct 20, 2025, 09:00 ET XGIMI Unveils Vibe by XGIMI: A Fresh Sub-Brand Bringing Projectors to a New Generation
should spark joy, not disappointment. With Vibe One, we're giving users a product that's simple, fun, and dependable, while still carrying the design DNA XGIMI is known for," said Apollo Zhong, Chairman at XGIMI. Continuous Momentum for the Projector
More news about: XGIMI
Oct 20, 2025, 08:00 ET MMC Elevates Beauty into Standalone Practice
"Beauty has always been central to MMC's DNA," said Fleming. "We see it as a personal expression that sparks joy, and our role is to help brands tap into that emotional resonance to build
More news about: Marina Maher Communications
Oct 20, 2025, 05:30 ET WuXi Biologics Honored with 2025 Global Customer Value Leadership Recognition by Frost & Sullivan
portfolio includes 326 mAbs, 168 bispecifics & multispecifics, 225 ADCs, 80 fusion proteins, and 25 vaccines. The development time for mAbs from DNA to Investigational New Drug (IND) application has been shortened to 9 months, with an autoimmune disease project completed in just 6 months. By combining
More news about: WuXi Biologics
Oct 20, 2025, 04:57 ET The New England Journal of Medicine Publishes Results of Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan in Advanced EGFR-TKI-Resistant NSCLC
antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment.
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 20, 2025, 03:25 ET EXEED Co-Creation Workshop: Texxeract Technology Premieres, Three New Models Debut with the New Family Design Language
its sporty character with a revised bumper, air-guiding side skirts, and a large rear diffuser. All three models inherit the Stellar Concept design DNA, showcasing the distinctive charm of EXEED's new family design language. Conclusion:
More news about: EXEED
Oct 20, 2025, 02:31 ET EXEED Co-Creation Workshop: Texxeract Technology Premieres, Three New Models Debut with the New Family Design Language
its sporty character with a revised bumper, air-guiding side skirts, and a large rear diffuser. All three models inherit the Stellar Concept design DNA, showcasing the distinctive charm of EXEED's new family design language. Conclusion:
More news about: EXEED
Oct 20, 2025, 01:56 ET Chengdu CATANIA's Tower 2 Debuts Globally: A 222-Meter-High Sky Residence Redefining Global Luxury Living.
club turn your daily living into a showroom. The Tower 2 epitomizes a sophisticated synthesis of artistic DNA and luxury living. The building facade, a masterpiece personally designed by the international luxury maestro Giorgio Armani, artfully blends the Oriental
More news about: CNS
Oct 19, 2025, 22:01 ET Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM
antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment.
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 19, 2025, 05:00 ET Jackaroo King Concludes Its 3rd Offline Championship in Dubai
within the Middle Eastern player community. Building Community and Experience: Strengthening the Social DNA As a product that has topped regional app store charts for consecutive months, Jackaroo King continues
More news about: Jackaroo King
Oct 19, 2025, 00:39 ET From Presentation to Full-Service Reception: AiMOGA Robot Demonstrates "Human Assistant" Capabilities at the 2025 Chery Global Innovation Conference
natural extension of Chery's innovation strategy. Technological Foundation: Robotics Grown from Automotive DNA The technology system of AiMOGA Robotics is rooted in Chery's vehicle-engineering platform.
More news about: AiMOGA Robotics
Oct 18, 2025, 10:42 ET Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO
antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment.
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 17, 2025, 11:51 ET OPPO leva Reno14 à São Paulo Fashion Week e reforça conexão entre tecnologia e criatividade
potencial da marca no universo da moda e da criação de conteúdo. "A SPFW é o maior evento de moda do hemisfério sul e traduz valores que também estão no DNA da OPPO: inovação, criatividade e lifestyle. Participar desse cenário é uma forma de conectar nossa tecnologia ao universo da moda e dialogar com um
More news about: OPPO Brasil
Oct 17, 2025, 11:39 ET A.D.A.M. Innovations und SOPHiA GENETICS kooperieren, um Flüssigbiopsie-Tests und Begleitdiagnostik für Präzisionsonkologie in Japan voranzutreiben
mit einer einzigen Blutentnahme verwertbare genomische Veränderungen nachzuweisen. Er nutzt modernste künstliche Intelligenz, um zirkulierende Tumor-DNA (ctDNA) auf minimalinvasive Weise zu analysieren. Der Test verwendet einen abgestimmten Tumor-Normal-Ansatz, der die Genauigkeit verbessert und falsch-positive
More news about: SOPHiA GENETICS
Oct 17, 2025, 09:37 ET A.D.A.M. Innovations en SOPHiA GENETICS werken samen om vloeibare biopsietests en begeleidende diagnostiek voor precisieloncologie te bevorderen in Japan
is ontworpen om bruikbare genoomveranderingen te detecteren vanuit een enkel bloedmonster, waarbij met behulp van geavanceerde AI circulerend tumor-DNA (ctDNA) op een minimaal invasieve manier wordt geanalyseerd. De test maakt gebruik van een gematchte tumor-normaal-benadering die de nauwkeurigheid verbetert
More news about: SOPHiA GENETICS
Oct 17, 2025, 09:00 ET Getac Integrates Semtech AirLink® for Mission-Critical Connectivity
defense, utility, and industrial sectors," said Rick Geisendorff, VP of Sales & Marketing, Getac North America. "Through pairing Getac's rugged DNA with Semtech's cellular technology, customers benefit from always-on connectivity, seamless backup between 5G, LTE, Wi-Fi, and satellite, and support
More news about: Getac
Oct 17, 2025, 09:00 ET Asymmetric Capital Partners Announces $137 Million Fund II to Back Early Stage Founders
concentration, and real operational support. The firm invests in disruptive technology-driven companies in the Pre-seed through Series A stages. Asymmetric's DNA is different by design: its team blends rigorous investing experience with hands-on operating expertise, having built, scaled, and acquired companies
More news about: Asymmetric Capital Partners
Oct 17, 2025, 08:15 ET MEDIA ADVISORY - MDA SPACE TO HOLD ITS THIRD QUARTER 2025 EARNINGS CONFERENCE CALL ON NOVEMBER 14, 2025
vision into an achievable mission – bringing to bear a one-of-a-kind mix of experience, engineering excellence and wide-eyed wonder that's been in our DNA since day one. For those who dream big and push boundaries on the ground and in the stars to change the world for the better, we'll take you there. For
More news about: MDA Space
Oct 17, 2025, 02:53 ET MVZ HPH Brings ctDNA Blood Test for Cancer Monitoring to Europe, Based on Haystack MRD® Technology from Quest Diagnostics®
/PRNewswire/ -- MVZ HPH Institute for Pathology and Hematopathology GmbH, today announced the availability of HPH MRD, a new tumor-informed circulating-tumor DNA (ctDNA) blood test for detecting minimal residual disease (MRD) in patients diagnosed with solid tumor cancers. The HPH MRD test is an in-house test
More news about: Quest Diagnostics